Baxter ROE 2010-2024 | BAX
Current and historical return on equity (ROE) values for Baxter (BAX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Baxter ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-06-30 | $2.48B | $7.71B | 30.40% |
| 2024-03-31 | $2.65B | $8.24B | 34.74% |
| 2023-12-31 | $2.66B | $8.47B | 37.67% |
| 2023-09-30 | $2.59B | $8.17B | 40.45% |
| 2023-06-30 | $-2.85B | $5.63B | -49.52% |
| 2023-03-31 | $-2.46B | $5.94B | -37.39% |
| 2022-12-31 | $-2.43B | $5.90B | -32.99% |
| 2022-09-30 | $-2.38B | $5.58B | -29.04% |
| 2022-06-30 | $1.01B | $8.90B | 11.25% |
| 2022-03-31 | $1.06B | $9.12B | 11.88% |
| 2021-12-31 | $1.28B | $9.12B | 14.69% |
| 2021-09-30 | $1.21B | $8.82B | 14.05% |
| 2021-06-30 | $1.12B | $8.54B | 13.04% |
| 2021-03-31 | $1.07B | $8.49B | 12.57% |
| 2020-12-31 | $1.10B | $8.73B | 13.27% |
| 2020-09-30 | $0.91B | $8.60B | 11.25% |
| 2020-06-30 | $0.92B | $8.16B | 11.76% |
| 2020-03-31 | $0.99B | $7.73B | 12.75% |
| 2019-12-31 | $1.00B | $7.91B | 12.90% |
| 2019-09-30 | $1.32B | $7.62B | 17.04% |
| 2019-06-30 | $1.47B | $7.84B | 18.09% |
| 2019-03-31 | $1.50B | $7.67B | 17.89% |
| 2018-12-31 | $1.55B | $7.87B | 17.70% |
| 2018-09-30 | $1.06B | $9.11B | 11.76% |
| 2018-06-30 | $0.80B | $8.87B | 8.73% |
| 2018-03-31 | $0.72B | $9.09B | 7.81% |
| 2017-12-31 | $0.60B | $9.12B | 6.61% |
| 2017-09-30 | $1.03B | $9.46B | 11.59% |
| 2017-06-30 | $0.91B | $9.17B | 10.46% |
| 2017-03-31 | $1.86B | $8.68B | 21.76% |
| 2016-12-31 | $4.97B | $8.28B | 57.61% |
| 2016-09-30 | $4.93B | $8.66B | 56.21% |
| 2016-06-30 | $4.80B | $8.51B | 56.05% |
| 2016-03-31 | $3.92B | $9.02B | 46.43% |
| 2015-12-31 | $0.97B | $8.87B | 12.09% |
| 2015-09-30 | $1.72B | $7.85B | 21.92% |
| 2015-06-30 | $2.18B | $8.02B | 27.38% |
| 2015-03-31 | $2.37B | $7.29B | 29.13% |
| 2014-12-31 | $2.50B | $8.16B | 29.41% |
| 2014-09-30 | $1.87B | $8.43B | 21.81% |
| 2014-06-30 | $1.95B | $8.69B | 23.16% |
| 2014-03-31 | $2.02B | $8.69B | 25.01% |
| 2013-12-31 | $2.01B | $8.49B | 26.35% |
| 2013-09-30 | $2.18B | $7.75B | 30.03% |
| 2013-06-30 | $2.22B | $7.32B | 31.16% |
| 2013-03-31 | $2.29B | $7.00B | 32.97% |
| 2012-12-31 | $2.33B | $6.98B | 33.54% |
| 2012-09-30 | $2.30B | $7.19B | 33.27% |
| 2012-06-30 | $2.29B | $6.61B | 33.17% |
| 2012-03-31 | $2.24B | $6.96B | 31.77% |
| 2011-12-31 | $2.22B | $6.83B | 31.51% |
| 2011-09-30 | $2.18B | $7.19B | 30.98% |
| 2011-06-30 | $2.13B | $7.24B | 30.72% |
| 2011-03-31 | $2.05B | $6.97B | 30.80% |
| 2010-12-31 | $1.42B | $6.80B | 21.55% |
| 2010-09-30 | $1.57B | $6.76B | 23.27% |
| 2010-06-30 | $1.57B | $6.13B | 22.87% |
| 2010-03-31 | $1.63B | $6.66B | 23.09% |
| 2009-12-31 | $2.21B | $7.42B | 31.88% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $19.851B | $14.813B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $195.617B | 25.27 |
| Stryker (SYK) | United States | $137.290B | 32.08 |
| Boston Scientific (BSX) | United States | $122.743B | 37.38 |
| Medtronic (MDT) | Ireland | $114.552B | 17.05 |
| EssilorLuxottica (ESLOY) | France | $108.842B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.651B | 35.57 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.030B | 0.00 |
| ResMed (RMD) | United States | $35.117B | 30.92 |
| Koninklijke Philips (PHG) | Netherlands | $30.774B | 23.39 |
| Terumo (TRUMY) | Japan | $28.517B | 40.27 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.039B | 13.87 |
| Insulet (PODD) | United States | $16.269B | 68.45 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.605B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.247B | 30.63 |
| Demant (WILYY) | Denmark | $8.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.898B | 33.39 |
| Lantheus Holdings (LNTH) | United States | $7.454B | 17.89 |
| ICU Medical (ICUI) | United States | $4.261B | 40.67 |
| Haemonetics (HAE) | United States | $4.084B | 20.20 |
| TG Therapeutics (TGTX) | United States | $3.689B | 39.07 |
| Neogen (NEOG) | United States | $3.599B | 37.75 |
| Prestige Consumer Healthcare (PBH) | United States | $3.534B | 17.61 |
| GN Store Nord (GNNDY) | Denmark | $3.509B | 21.14 |
| Perrigo (PRGO) | Ireland | $3.499B | 11.06 |
| Envista Holdings (NVST) | United States | $3.398B | 18.13 |
| QuidelOrtho (QDEL) | United States | $3.063B | 19.30 |
| Agios Pharmaceuticals (AGIO) | United States | $2.595B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.226B | 37.36 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.124B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.061B | 54.92 |
| Warby Parker (WRBY) | United States | $1.614B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.497B | 10.81 |
| InMode (INMD) | Israel | $1.464B | 9.32 |
| AtriCure (ATRC) | United States | $1.372B | 0.00 |
| Owens & Minor (OMI) | United States | $1.247B | 9.63 |
| Verano Holdings (VRNOF) | United States | $1.184B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.123B | 0.00 |
| Evolus (EOLS) | United States | $1.006B | 0.00 |
| PetIQ (PETQ) | United States | $0.919B | 23.30 |
| Phibro Animal Health (PAHC) | United States | $0.894B | 18.55 |
| National Vision Holdings (EYE) | United States | $0.867B | 27.55 |
| Cresco Labs (CRLBF) | United States | $0.805B | 0.00 |
| Surmodics (SRDX) | United States | $0.549B | 116.64 |
| Quanterix (QTRX) | United States | $0.489B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.488B | 14.72 |
| Jin Medical (ZJYL) | China | $0.439B | 0.00 |
| ZimVie (ZIMV) | United States | $0.435B | 40.41 |
| Valneva SE (VALN) | France | $0.432B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.402B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.389B | 0.00 |
| Cerus (CERS) | United States | $0.324B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.324B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.320B | 8.25 |
| Aurora Cannabis (ACB) | Canada | $0.319B | 0.00 |
| Biote (BTMD) | United States | $0.307B | 14.18 |
| Viemed Healthcare (VMD) | United States | $0.283B | 30.38 |
| Sanara MedTech (SMTI) | United States | $0.264B | 0.00 |
| Zynex (ZYXI) | United States | $0.257B | 45.00 |
| Utah Medical Products (UTMD) | United States | $0.232B | 15.41 |
| Omeros (OMER) | United States | $0.227B | 0.00 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.194B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.191B | 0.00 |
| High Tide (HITI) | Canada | $0.163B | 67.33 |
| FitLife Brands (FTLF) | United States | $0.153B | 20.64 |
| Brainsway (BWAY) | Israel | $0.135B | 161.40 |
| TriSalus Life Sciences (TLSI) | United States | $0.130B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.121B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.114B | 0.00 |
| Veru (VERU) | United States | $0.113B | 0.00 |
| Fonar (FONR) | United States | $0.111B | 11.44 |
| Jushi Holdings (JUSHF) | United States | $0.104B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.101B | 24.80 |
| InterCure (INCR) | Israel | $0.087B | 14.62 |
| Zevia PBC (ZVIA) | United States | $0.083B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.082B | 0.00 |
| Modular Medical (MODD) | United States | $0.074B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.073B | 0.00 |
| Safety Shot (SHOT) | United States | $0.071B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.051B | 3.35 |
| Apyx Medical (APYX) | United States | $0.042B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.040B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.008B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.007B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 21.30 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |